Aortic Regurgitation
One-fourth of older adults with no history of CVD may have asymptomatic valvular disease
More than one-fourth of individuals aged 60 years or older with no history of heart disease may have asymptomatic valvular heart disease, according to a U.K. study published in the European Heart Journal – Cardiovascular Imaging.
ALIGN AR: ‘Intuitive’ TAVR system safe, effective for severe aortic regurgitation
SAN FRANCISCO — New 1-year data show a novel system for transcatheter aortic valve replacement was safe and effective for adults with symptomatic severe aortic regurgitation at high surgical risk, a speaker reported at TCT 2023.
Bioprosthetic valve dysfunction less common in TAVR vs. surgery at 5 years
In a pooled analysis of two trials comparing self-expanding transcatheter aortic valve replacement with surgical AVR, bioprosthetic valve dysfunction was less common with TAVR at 5 years, researchers reported.
Self-expanding TAVR tied to less structural valve deterioration at 5 years vs. surgery
Transcatheter aortic valve replacement using a self-expanding bioprosthesis was associated with lower risk for structural valve deterioration vs. surgical valve replacement at 5 years, researchers reported.
After TAVR, overweight tied to lower mortality, adverse event rates
After transcatheter aortic valve replacement, patients with BMI more than 25 kg/m2 had less all-cause mortality, aortic regurgitation and MI compared with those under that threshold, according to a meta-analysis.
Changes in devices, procedures major driver of improvement in TAVR outcomes
BOSTON — Changes in devices and procedural care were the biggest factor in improvements in short-term outcomes for patients undergoing transcatheter aortic valve replacement, researchers reported at TCT 2022.
More data confirm improved hemodynamics with next-generation TAVR valve
Pooled data from two registries have confirmed a previous report that a next-generation transcatheter aortic valve replacement system confers less paravalvular aortic regurgitation compared with the previous generation.
Novel TAVR system safe, effective for patients with severe aortic regurgitation
A novel system for transcatheter aortic valve replacement was safe and effective for a small cohort of patients with severe aortic regurgitation who were ineligible or at high risk for surgery, according to a real-world data analysis.
Next-generation TAVR valve confers less paravalvular aortic regurgitation vs. predecessor
A next-generation transcatheter aortic valve replacement system was associated with less paravalvular aortic regurgitation compared with an earlier version, researchers reported at EuroPCR.
Severe valvular disease, COVID-19 mortality ‘approaching’ 50% at 30 days
Thirty-day mortality among patients with severe valvular heart disease and COVID-19 topped more than 40%, according to data presented at the virtual Society for Cardiovascular Angiography and Interventions Scientific Sessions.